Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention

Abstract Backgrounds Diabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has i...

Full description

Bibliographic Details
Main Authors: H. Zhang, H. Fu, X. Fu, J. Zhang, P. Zhang, S. Yang, Z. Zeng, N. Fu, Z. Guo
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Nephrology
Subjects:
Online Access:https://doi.org/10.1186/s12882-021-02405-y
id doaj-43cf81e77ed94f4f96db33d6ea97ae7f
record_format Article
spelling doaj-43cf81e77ed94f4f96db33d6ea97ae7f2021-06-06T11:50:43ZengBMCBMC Nephrology1471-23692021-06-012211710.1186/s12882-021-02405-yGlycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary interventionH. Zhang0H. Fu1X. Fu2J. Zhang3P. Zhang4S. Yang5Z. Zeng6N. Fu7Z. Guo8Clinical College of Chest,Tianjin Medical UniversityTianjin Medical UniversityTianjin Medical UniversityDepartment of Cardiology, Tianjin Chest HospitalDepartment of Cardiology, Tianjin Chest HospitalDepartment of Cardiology, Tianjin Chest HospitalTianjin Medical UniversityDepartment of Cardiology, Tianjin Chest HospitalDepartment of Cardiology, Tianjin Chest HospitalAbstract Backgrounds Diabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN. Methods We reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48 h and 72 h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher’s exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN. Results Patients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48 h and 72 h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p < 0.0001) The multivariate analysis confirmed that in the main high-risk subgroup, patients with elevated HbA1C levels (≥8.8%) had a higher risk of CIN disease. Trend test showed the change of OR (1.000,1.248,1.553,2.625,5.829). Conclusions Studies have shown that in diabetic patients undergoing CAG/PCI, elevated HbA1c is independently associated with the risk of CIN, and when HbA1c > 9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN.https://doi.org/10.1186/s12882-021-02405-yDiabetes mellitusGlycosylated hemoglobinPercutaneous coronary interventionContrast-induced nephropathyRisk factors
collection DOAJ
language English
format Article
sources DOAJ
author H. Zhang
H. Fu
X. Fu
J. Zhang
P. Zhang
S. Yang
Z. Zeng
N. Fu
Z. Guo
spellingShingle H. Zhang
H. Fu
X. Fu
J. Zhang
P. Zhang
S. Yang
Z. Zeng
N. Fu
Z. Guo
Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
BMC Nephrology
Diabetes mellitus
Glycosylated hemoglobin
Percutaneous coronary intervention
Contrast-induced nephropathy
Risk factors
author_facet H. Zhang
H. Fu
X. Fu
J. Zhang
P. Zhang
S. Yang
Z. Zeng
N. Fu
Z. Guo
author_sort H. Zhang
title Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
title_short Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
title_full Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
title_fullStr Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
title_full_unstemmed Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
title_sort glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
publisher BMC
series BMC Nephrology
issn 1471-2369
publishDate 2021-06-01
description Abstract Backgrounds Diabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN. Methods We reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48 h and 72 h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher’s exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN. Results Patients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48 h and 72 h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p < 0.0001) The multivariate analysis confirmed that in the main high-risk subgroup, patients with elevated HbA1C levels (≥8.8%) had a higher risk of CIN disease. Trend test showed the change of OR (1.000,1.248,1.553,2.625,5.829). Conclusions Studies have shown that in diabetic patients undergoing CAG/PCI, elevated HbA1c is independently associated with the risk of CIN, and when HbA1c > 9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN.
topic Diabetes mellitus
Glycosylated hemoglobin
Percutaneous coronary intervention
Contrast-induced nephropathy
Risk factors
url https://doi.org/10.1186/s12882-021-02405-y
work_keys_str_mv AT hzhang glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT hfu glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT xfu glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT jzhang glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT pzhang glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT syang glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT zzeng glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT nfu glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
AT zguo glycosylatedhemoglobinlevelsandtheriskforcontrastinducednephropathyindiabeticpatientsundergoingcoronaryarteriographypercutaneouscoronaryintervention
_version_ 1721393576616656896